Skip to content

Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population

Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00533754
Enrollment
Unknown
Registered
2007-09-21
Start date
2006-07-31
Completion date
2007-11-30
Last updated
2007-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration

Keywords

age-related macular degeneration, genetics

Brief summary

The aim of the study is to show a higher expression of the Y402H polymorphism in the complement factor H in patients with AMD compared to healthy individuals. Additionaly a correlation between a subsided infection with chlamydia and patients with AMD and a factor H polymorphism will be investigated. An interrelationship with the VEGF-plasma level shall give more hints into the pathomechanism of AMD.

Interventions

PROCEDUREdrawing blood

Sponsors

Rudolf Foundation Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* man and women over 18 years old * Filled out informed consentBereitschaft zur Teilnahme * Diagnosis of non-exudative/ exudative age related macular dgeneneration

Exclusion criteria

* inherited retinal diseases * other aquired retinal/ macular * missing informed consent

Design outcomes

Primary

MeasureTime frame
higher expression of the Y402H polymorphism in the complement factor H in patients with AMD compared to healthy individuals

Secondary

MeasureTime frame
a correlation between a subsided infection with chlamydia and patients with AMD and a factor H polymorphism will be investigated. An interrelationship with the VEGF-plasma level shall give more hints into the pathomechanism of AMD

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026